Ciprofloxacin/Celecoxib Combination in Patients With ALS
Status:
Active, not recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
This is an open label, off label study, to provide interested ALS patients with
Ciprofloxacin/Celecoxib fixed dose combination, while assessing safety and tolerability,
routine disease progression measures (ALSFRS-R and Vital Capacity).